nucleic acid segments of the present invention may thus be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably
This rigorous evaluation has led to the accelerated recognition of the cardioprotective, renoprotective, and vasoprotective effects of SGLT2i ( Figure 1 )
Certain preferred second biological agents, components or systems are prodrugs or components for making and using prodrugs, including components for making the prodrug itself and components for adapting the antibodies of the invention to function in such prodrug or ADEPT embodiments
they seek insights that help them make better decisions
Furthermore, expanding access to oral therapies across emerging markets is creating new growth opportunities